The Prognostic and Predictive Value of the Combination of the Neutrophil-to-lymphocyte Ratio and the Platelet-to-lymphocyte Ratio in Patients with Hepatocellular Carcinoma Who Receive Transarterial Chemoembolization Therapy

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Mar 14

PMID 30863150

Citations 24

Authors

Chaobin He

Yu Zhang

Zhiyuan Cai

Xiaojun Lin

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was designed to evaluate the prognostic value of the combination of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) (neutrophil/platelet-to-lymphocyte ratio [NLR-PLR]) in patients with hepatocellular carcinoma (HCC) who receive transarterial chemoembolization (TACE) therapy.

Patients And Methods: Data from 216 patients who were diagnosed with HCC after TACE therapy were retrospectively collected. R software was used to analyze the time-dependent receiver operating characteristic (ROC) curves and to compare the area under the ROC curves (AUROCs).

Results: The long-term survival rates were significantly higher for patients with lower values than those with higher values of NLR, PLR, and NLR-PLR. The mean overall survival decreased gradually with increases in the NLR-PLR score (<0.0001). The AUROC values of the NLR-PLR score were consistently higher than those of NLR and PLR.

Conclusion: This study showed that the NLR-PLR score might be a useful predictor for patients with HCC who receive TACE therapy.

Citing Articles

Multisequence MRI-Based Radiomic Features Combined with Inflammatory Indices for Predicting the Overall Survival of HCC Patients After TACE.

Zhou M, Zhang P, Mao Q, Shi Y, Yang L, Zhang X J Hepatocell Carcinoma. 2024; 11:2049-2061.

PMID: 39469284 PMC: 11514804. DOI: 10.2147/JHC.S481301.

Proliferative vitreoretinopathy and its relationship with inflammatory serum biomarkers.

Martinez Pacheco V, Rojas Juarez S, Velasco Sepulveda B, Ramirez Estudillo A Int J Ophthalmol. 2024; 17(9):1659-1664.

PMID: 39296565 PMC: 11367444. DOI: 10.18240/ijo.2024.09.13.

Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis.

Wang S, Geng H, Li Y, Xu Z, Yang K, Yang L Heliyon. 2024; 10(9):e30759.

PMID: 38765170 PMC: 11098848. DOI: 10.1016/j.heliyon.2024.e30759.

Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma.

Yanagaki M, Onda S, Gocho T, Igarashi Y, Shirai Y, Okui N Langenbecks Arch Surg. 2024; 409(1):130.

PMID: 38634913 DOI: 10.1007/s00423-024-03315-x.

Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma.

Chen X, Mohammed A, Li C Clin Appl Thromb Hemost. 2024; 30:10760296231221535.

PMID: 38591958 PMC: 11005495. DOI: 10.1177/10760296231221535.

References

Jaiswal M, Larusso N, Burgart L, Gores G . Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; 60(1):184-90. View

Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H . Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000; 88(3):577-83. View

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

Liu C, Chang S, Narko K, Trifan O, Wu M, Smith E . Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001; 276(21):18563-9. DOI: 10.1074/jbc.M010787200. View

Li Y, Yu D, Chen Y, Amin P, Zhang H, Nguyen N . A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001; 61(17):6428-36. View

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

Schoppmann S, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C . Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002; 161(3):947-56. PMC: 1867252. DOI: 10.1016/S0002-9440(10)64255-1. View

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

Llovet J, Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2):429-42. DOI: 10.1053/jhep.2003.50047. View

10.

Llovet J, Burroughs A, Bruix J . Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907-17. DOI: 10.1016/S0140-6736(03)14964-1. View

11.

Dannenberg A, Subbaramaiah K . Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2004; 4(6):431-6. DOI: 10.1016/s1535-6108(03)00310-6. View

12.

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

13.

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

14.

Fluss R, Faraggi D, Reiser B . Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47(4):458-72. DOI: 10.1002/bimj.200410135. View

15.

Bruix J, Sherman M . Management of hepatocellular carcinoma. Hepatology. 2005; 42(5):1208-36. DOI: 10.1002/hep.20933. View

16.

de Visser K, Eichten A, Coussens L . Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6(1):24-37. DOI: 10.1038/nrc1782. View

17.

Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M . Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol. 2008; 14(24):3819-28. PMC: 2721438. DOI: 10.3748/wjg.14.3819. View

18.

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

19.

Palmer D . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(23):2498. View

20.

Wiesner T, Bugl S, Mayer F, Hartmann J, Kopp H . Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis. 2010; 27(3):141-9. DOI: 10.1007/s10585-010-9311-6. View